BMS-P5 |
Catalog No.GC48495
One-Click Copy Product Info
|
BMS-P5는 특이적 경구 활성 펩티딜아르기닌 데이미나제 4(PAD4) 억제제입니다. BMS-P5는 동계 마우스 모델에서 MM 유도 NET 형성을 차단하고 MM의 진행을 지연시킵니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1550371-22-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BMS-P5 is a novel, orally active selective inhibitor of peptidylarginine deiminase 4 (PAD4) with an IC50 of 98nM. BMS-P5 blocks multiple myeloma-induced neutrophil extracellular trap (NET) formation. BMS-P5 can be used for research related to multiple myeloma[1-2].
In vivo, starting from day 3 after tumor cell injection, BMS-P5 (50mg/kg; twice daily) was administered by oral gavage to a multiple myeloma mouse model induced by DP42 cells for 20 days. BMS-P5 significantly delayed symptom development and prolonged survival[2].
References:
[1] Cîrciumaru A, Afonso MG, Wähämaa H, et al. Anti-Citrullinated Protein Antibody Reactivity towards Neutrophil-Derived Antigens: Clonal Diversity and Inter-Individual Variation. Biomolecules. 2023 Mar 31;13(4):630.
[2] Li M, Lin C, Deng H, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19(7):1530-1538.
| Animal experiment [1]: | |
Animal models | F1 progeny of mixed C57BL/6FVB/N background mice |
Preparation Method | Multiple myeloma tumors were established by i.v. inoculation into the tail vein of DP42 cells (5×10³). Starting from the third day after tumor cell injection, BMS-P5 (50mg/kg; twice daily) was administered orally in a multiple myeloma mouse model induced by DP42 cells for 20 days. |
Dosage form | 50mg/kg; oral gavage; twice a day for 20 days |
Applications | BMS-P5 administration significantly delayed development of symptoms (paralysis and hunched posture) and significantly prolonged survival of MM-bearing mice. |
References: | |
| Cas No. | 1550371-22-6 | SDF | |
| Canonical SMILES | CN1C(C2=CC3=CC=CN=C3N2CC4CC4)=NC5=CC(C(N6[C@H](CC[C@H](C6)N)C)=O)=CC(OC)=C15 | ||
| Formula | C27H32N6O2 | M.Wt | 472.6 |
| Solubility | DMF: 20 mg/ml,DMSO: 5 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:8): 0.11 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.116 mL | 10.5798 mL | 21.1595 mL |
| 5 mM | 423.2 μL | 2.116 mL | 4.2319 mL |
| 10 mM | 211.6 μL | 1.058 mL | 2.116 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)